Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many AI claims are not supported by the label excerpts provided (e.g., named indications, specific mechanism details, ophthalmic formulation, adverse reaction examples, specific FDA warning content, and pregnancy counseling wording). Because large label sections referenced by the excerpt are not included, full alignment cannot be confirmed; however, numerous statements are evaluated as unsupported relative to the provided text.
Category Scores
Accurate Statements
Levofloxacin is an antibiotic.
12.1 INDICATIONS AND USAGE (treated as an antibacterial; used to treat/prevent infections due to susceptible bacteria).
Levofloxacin belongs to the class of drugs called fluoroquinolones.
12.1 Mechanism of Action: member of the fluoroquinolone class.
Levofloxacin is available in oral tablet form.
3 DOSAGE FORMS AND STRENGTHS: Tablets listed (250/500/750 mg).
Levofloxacin is available as an intravenous solution.
3 DOSAGE FORMS AND STRENGTHS: Injection described for IV infusion / concentrated solution for dilution.
Unsupported Statements
Levofloxacin is used to treat various bacterial infections.
Supported only in general by 1 INDICATIONS AND USAGE (treat/prevent infections caused by susceptible bacteria); the provided excerpt does not enumerate 'various' infections.
Levofloxacin is used to treat pneumonia.
Named indication (pneumonia) is not included in the provided 1 INDICATIONS AND USAGE excerpt text.
Levofloxacin is used to treat bronchitis.
Named indication (bronchitis) is not included in the provided 1 INDICATIONS AND USAGE excerpt text.
Levofloxacin is used to treat urinary tract infections.
Named indication (urinary tract infections) is not included in the provided 1 INDICATIONS AND USAGE excerpt text.
Levofloxacin is used to treat certain skin infections.
Named indication (skin infections) is not included in the provided 1 INDICATIONS AND USAGE excerpt text.
Levofloxacin works by stopping the growth of bacteria.
No such mechanism statement appears in the provided excerpts; 12.1 Mechanism excerpt only states fluoroquinolone class membership.
Levofloxacin interferes with bacterial DNA replication.
DNA replication detail not present in provided excerpts.
Levofloxacin interferes with bacterial DNA transcription.
DNA transcription detail not present in provided excerpts.
Levofloxacin interferes with bacterial DNA repair.
DNA repair detail not present in provided excerpts.
Levofloxacin interferes with bacterial DNA recombination.
DNA recombination detail not present in provided excerpts.
Levofloxacin has patent expiration dates that vary depending on the specific patent and region.
No patent/expiration information is present in the provided label excerpts.
Levofloxacin is available as an ophthalmic solution for eye infections.
Provided 3 DOSAGE FORMS AND STRENGTHS excerpt lists tablets, oral solution, and injection; no ophthalmic solution is listed.
Common side effects of levofloxacin can include nausea.
6 ADVERSE REACTIONS section is referenced but the provided excerpts do not include adverse reaction details.
Common side effects of levofloxacin can include diarrhea.
6 ADVERSE REACTIONS details not included in provided excerpts.
Common side effects of levofloxacin can include headache.
6 ADVERSE REACTIONS details not included in provided excerpts.
Common side effects of levofloxacin can include dizziness.
6 ADVERSE REACTIONS details not included in provided excerpts.
Levofloxacin carries a risk of serious side effects.
No severity/risk wording is present in the provided excerpts.
Serious side effects of levofloxacin can include tendon rupture.
5 WARNINGS AND PRECAUTIONS is referenced but the provided excerpts do not include the specific tendon rupture warning content.
Serious side effects of levofloxacin can include nerve damage.
5 WARNINGS AND PRECAUTIONS is referenced but the provided excerpts do not include the specific nerve damage warning content.
Serious side effects of levofloxacin can include central nervous system effects.
5 WARNINGS AND PRECAUTIONS is referenced but the provided excerpts do not include the specific CNS effects warning content.
The U.S. Food and Drug Administration (FDA) has issued warnings regarding risks of tendon rupture, nerve damage, and central nervous system effects with levofloxacin.
Specific warning text is not present in the provided excerpts.
Levofloxacin should be used under the guidance of a healthcare professional.
No such instruction appears in the provided excerpts.
Alternative antibiotic classes may include macrolides.
No alternative antibiotic classes are listed in the provided excerpts.
Alternative antibiotic classes may include tetracyclines.
No alternative antibiotic classes are listed in the provided excerpts.
Alternative antibiotic classes may include beta-lactams.
No alternative antibiotic classes are listed in the provided excerpts.
Levofloxacin is manufactured by various pharmaceutical companies for branded and generic versions.
No manufacturing/company/branding information is present in the provided label excerpts.
The use of levofloxacin during pregnancy should be carefully considered and discussed with a healthcare provider.
8.1 Pregnancy is only listed, and the provided excerpts do not include the counseling wording.
The safety profile of levofloxacin in pregnant individuals is not fully established.
8.1 Pregnancy content is not provided in the excerpts; specific 'not fully established' wording is not shown.
Levofloxacin is a third-generation fluoroquinolone.
12.1 Mechanism excerpt only supports fluoroquinolone class membership; 'third-generation' descriptor is not provided.
Levofloxacin has a spectrum of activity that includes many common bacterial pathogens.
12.4 Microbiology content is referenced but not included in provided excerpts.
Levofloxacin is often considered more potent against certain bacteria compared to older fluoroquinolones like ciprofloxacin.
No comparative potency statements (including ciprofloxacin comparisons) are present in the provided excerpts.
Contradictions
Important Omissions
Named FDA-approved indications are not specified in the AI response (e.g., the specific 'designated microorganisms' and the listed conditions are not reproduced).
Importance:
Moderate
Dose selection/administration details (dose, frequency, renal adjustment, and route-specific instructions) are not provided by the AI response.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several AI claims assert specific safety warnings (tendon rupture, nerve damage, CNS effects) and pregnancy counseling/pregnancy safety language without support in the provided label excerpts. Additionally, named indications and formulation details (ophthalmic) are unsupported, which could mislead about use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple major claims are unsupported or include unverified details not present in the supplied label excerpts (named indications, mechanism specifics, adverse reactions/warning content, pregnancy counseling language, and ophthalmic formulation).
Suggested Improvement
Limit claims to what is explicitly supported by the provided label text (e.g., fluoroquinolone class, antibacterial stewardship language, tablet/IV injection dosage forms). Remove or qualify claims that are not present in the excerpts, especially those about specific indications, adverse reactions, FDA warnings, and pregnancy language.